

Level 2, 66 Hunter Street
Sydney NSW 2000
Tel: (61-2) 9300 3344
Fax: (61-2) 9221 6333
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

11 April 2017

The Manager Companies
ASX Limited
20 Bridge Street
Sydney NSW 2000

(2 pages by email)

Dear Madam

UPDATE ON PROGRESS OF BIT225 PHASE 2 HIV-1 CLINICAL TRIAL

Sydney, Australia, 11 April, 2017: Australian drug development company Biotron Limited (ASX:BIT) today provided an update on its mid-clinical stage program for treatment of HIV-1 with the Company's lead antiviral drug, BIT225.

A Phase 2 study (BIT225-009) of BIT225 is currently in progress at HIV-NAT, Thai Red Cross AIDS Research Centre in Bangkok, Thailand.

Following the receipt of additional ethics approvals, a second site, based in Chiang Mai, has now been initiated. Patient screening and enrolment of eligible subjects can now proceed at this site, in addition to the main trial site in Bangkok.

The trial is a Phase 2, multi-centre, randomised, placebo-controlled, double-blind study of BIT225 and Combination Antiretroviral Therapy (approved anti-HIV-1 drugs; cART) in patients with HIV-1 infection. Patients will not have previously been on anti-HIV-1 treatment (i.e. treatment naïve) and will be commencing a cART regimen. Patients will receive cART in addition to 12 weeks with BIT225 or placebo.

As previously advised, the trial includes a dose escalation, with an initial group of 9 patients receiving 100 mg BIT225 once daily, or placebo, together with cART. A second group of 27 patients will receive 200 mg BIT225 once daily, or placebo, together with cART. At the conclusion of the trial, patients will remain on cART as per standard treatment protocols.

Screening and enrolment of patients for the initial 100 mg cohort is currently underway at the Bangkok trial site.

Biotron's Managing Director, Dr. Michelle Miller said, "We are pleased to bring this second trial site on line. Good progress is being made and a second site will further advance this important study. This trial is designed to show a clear clinical benefit with BIT225 over standard treatment for HIV-1."

Early results from the trial are anticipated in late Q3 this year.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn8856

About Biotron

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for both HIV-1 and HCV and also has several earlier stage preclinical and research programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Dengue, Hepatitis B, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

Enquiries

Dr Michelle Miller
Managing Director
Biotron Limited
+61-(0)412313329

Rudi Michelson
Monsoon Communications
+61-3 9620 3333